Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2025 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2025 Earnings Call Transcript November 6, 2025Collegium Pharmaceutical, Inc. beats earnings expectations.
Collegium Pharmaceutical Inc (COLL)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 2,826,498 | $98,899,165 | -11% | 1.12% |
| 2. | Renaissance Technologies Jim Simons | 1,599,189 | $55,955,623 | +6% | 0.07% |
| 3. | 36,200,000 | $42,705,486 | 0.66% | ||
| 4. | D E Shaw D. E. Shaw | 389,775 | $13,638,227 | +92% | 0.01% |
| 5. | Royce & Associates Chuck Royce | 306,140 | $10,711,839 | +1% | 0.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.18 | 10,000 | $91,800.00 | 110,227 | 2017-05-12 | Filing | |
| $10.59 | 2,375 | $25,151.25 | 2,375 | 2016-08-12 | Filing | |
| $12.00 | 3,930 | $47,160.00 | 65,270 | 2015-05-12 | Filing | |
| $12.00 | 196,070 | $2,352,840.00 | 3,256,572 | 2015-05-12 | Filing | |
| $12.00 | 150,000 | $1,800,000.00 | 1,887,332 | 2015-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.03 | 3,650 | $171,673.37 | 52,629 | 2025-12-05 | Filing | |
| $47.21 | 34,853 | $1,645,535.60 | 64,634 | 2025-11-12 | Filing | |
| $41.28 | 4,858 | $200,516.86 | 126,667 | 2025-11-06 | Filing | |
| $40.38 | 25,142 | $1,015,236.47 | 131,525 | 2025-11-06 | Filing | |
| $38.42 | 17,478 | $671,576.42 | 70,264 | 2025-08-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,178,044 | $181,179,760 | 0% | |
| 2. | 112,690,000 | $133,478,906 | 0.89% | |
| 3. | 2,390,912 | $83,653,116 | 1.38% | |
| 4. | 2,226,378 | $77,900,966 | 0% | |
| 5. | 1,502,674 | $52,578,565 | 0.18% |
News See All
Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory
We came across a bullish thesis on Collegium Pharmaceutical, Inc. on The Catholic Capitalist’s Substack by Logan Shearer. In this article, we will summarize the bulls’ thesis on COLL.
Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025
Collegium Pharmaceutical, Inc.
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of prescription pharmaceuticals...
Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025
Collegium Pharmaceutical, Inc.
10 Overlooked Healthcare Stocks to Invest in
Most Americans have endured the frustration of having their health insurance denied, often with no resolution even after contacting carriers by phone and email. This can be changed by Dr.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Collegium Pharmaceuticals Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded.
12 Small Cap Stocks with High Upside Potential
The trade war saga between the U.S. and China appears to be nearing a conclusion, as China’s Ministry of Commerce shared details on the trade deal on June 27.
Collegium Pharmaceutical Announces Share Repurchase Program Worth $25 Million
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is one of the 12 Small Cap Stocks with High Upside Potential.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2025 Earnings Call Transcript
Operator: Greetings and welcome to the Collegium Pharmaceutical First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded.